Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus anlotinib in previously treated recurrent or metastatic nasopharyngeal carcinoma
ChiCTR2200056397Phase 2Recruiting
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Feb 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and anlotinib in nasopharyngeal carcinoma (NPC), sponsored by The Second Affiliated Hospital of Nanchang University. Primary endpoint: Median progression-free survival. Started Feb 2022; status: recruiting.
02
Drugs
camrelizumabanlotinib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2200056397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056397.